NY-CALVIN-KLEIN-INC
3.8.2020 13:02:08 CEST | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide global advertising campaign for ETERNITY Calvin Klein with the return of maternal health activist and model Christy Turlington Burns, alongside her husband, director, writer, producer and actor Edward Burns, as the faces of the ETERNITY campaign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005090/en/
ETERNITY Calvin Klein advertising has artfully and unforgettably captured the promise of romance, intimacy, and commitment. Together, Turlington Burns who starred in the first ETERNITY advertising campaign when it debuted in 1988, and Burns who has appeared next to his wife in the 2014 and 2016 campaigns, bring to life the essence of the ETERNITY love story with their timeless relationship.
Today, the ETERNITY story continues with the iconic couple in a new television and print campaign that portrays an enduring love rooted in sensuality, authenticity, spontaneity, and supports the launch of the new ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein.
“After shooting the first ETERNITY Calvin Klein campaign ever over 30 years ago, it’s a pleasure to be working with Calvin Klein again and to continue to be a part of the history of such an iconic fragrance,” said Turlington Burns + Burns jointly. “We are honored to be part of this new campaign celebrating our relationship with ETERNITY Calvin Klein.”
The television campaign is captured by filmmaker and photographer Matt Lambert and is a combination of traditional black and white in addition to color shots. This juxtaposition conveys their committed past with the strength of their present relationship. The campaign, a compilation of joyful moments by the ocean, is an homage to their love story and is set to a reimagined cover of the iconic love song ‘Unchained Melody’ by Lykke Li.
Lachlan Bailey photographed the iconic couple in a classic black and white still campaign visual on the beach. Turlington Burns' hair is effortlessly being swept back by the ocean breeze while Burns adoringly pulls her toward him. The image is just one of many memories in time for the couple, a stolen moment in their endless love story.
“We are thrilled to welcome back such an iconic couple to celebrate the next chapter of ETERNITY Calvin Klein which continues its legacy as one of the most beloved fragrances for both men and women,” said Simona Cattaneo, President of Luxury Brands at Coty. “With this new campaign ETERNITY continues to inspire timeless love; its romantic values are undimmed by the passing of time and still resonate with consumers today.”
In addition to supporting ETERNITY Calvin Klein Signature, the campaign also supports the new line extension ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein through the still campaign visual also shot by Bailey. The hero image is an injection of happiness and bursts of freshness; Turlington Burns and Burns are captured playfully frolicking in the ocean, holding each other closely as the waves splash around them.
Evoking the free-spirited nature of the ocean and the joy of strolling through a beautiful sensual garden, the line extension inspires spontaneity while celebrating the spirit of eternal love. The enduring legacy of the ETERNITY Calvin Klein Signature is playfully reimagined for modern lovers with fresh green ingredients in ETERNITY Cologne for him Calvin Klein by perfumers Julie Massé, Ralf Schwieger and Véronique Nyberg of Mane and romantic watery florals in ETERNITY Eau Fresh for her Calvin Klein by perfumers Olivier Gillotin and Sonia Constant of Givaudan.
ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein are available for sale globally starting today on a rolling basis.
About Calvin Klein, Inc.:
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $9 billion in 2019 and were distributed in over 110 countries. Calvin Klein employs over 11,500 associates globally. We were acquired by PVH Corp. in 2003.
About COTY Inc.
Coty is one of the world’s largest beauty companies with approximately $9 billion in revenue, with a purpose to celebrate and liberate the diversity of consumers’ beauty. Its strong entrepreneurial heritage has created an iconic portfolio of leading beauty brands. Coty is the global leader in fragrance, a strong number two in professional salon hair color & styling, and number three in color cosmetics. Coty operates three divisions – Coty Consumer Beauty, which is focused on color cosmetics, retail hair coloring and styling products, body care and mass fragrances sold primarily in the mass retail channels with brands such as Bourjois, Max Factor, Rimmel, Wella, Adidas and Guess; Coty Luxury, which is focused on prestige fragrances and skincare with brands such as Gucci, Hugo Boss, Calvin Klein, Chloe, Bottega Veneta and Alexander McQueen; and Coty Professional Beauty, which is focused on servicing salon owners and professionals in both hair and nail, with brands such as Wella Professionals, System Professional, OPI and ghd. Coty has approximately 20,000 colleagues globally and its products are sold in over 130 countries. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
ADVERTISING CREDITS:
Creative Direction: Calvin Klein and Mazarine
Campaign Videos: Matt Lambert
Advertising Campaign images: Lachlan Bailey
EDITORIAL CREDIT:
ETERNITY For Women Eau de Parfum CALVIN KLEIN
ETERNITY For Men Eau de toilette CALVIN KLEIN
ETERNITY Eau Fresh for her CALVIN KLEIN
ETERNITY Cologne for him CALVIN KLEIN
TVC: https://youtu.be/NN9Q2pKiDKE
SOCIAL MEDIA: #cketernity
BRAND HANDLE: @calvinklein
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom